FBRX earnings analysis
What we found in FBRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing does not provide quarterly revenue, margins, EPS, segment results, operating cash flow or free cash flow, preventing a period-over-period earnings trend assessment. Liquidity is a near-term positive, with approximately $198.5 million of cash and investments and a stated runway of at least 12 months, supported by a $172.5 million April equity offering and a $500.0 million shelf registration. However, Forte remains an unprofitable, single-asset clinical-stage company with a $45.5 million six-month net loss, and the pending argenx transaction introduces substantial closing, execution and valuation risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $198.5M liquidity supports 12-month runway
- Forte reported approximately $198.5 million of cash, cash equivalents and short-term investments as of June 30, 2026, and expects existing resources to fund operations for at least 12 months from the filing date.
- $172.5M equity raise completed
- Forte closed a 2026 Offering generating $172.5 million of gross proceeds, though underwriting discounts, commissions and offering expenses were approximately $11.1 million.
- FB102 clinical program advanced
- Forte reported positive topline data from the FB102 Phase 1b vitiligo trial in July 2026 and is conducting a Phase 2 celiac study and a Phase 1b alopecia areata trial, with topline readouts expected in the second half of 2026.
- Lean 23-person organization
- Forte had 23 full-time employees as of June 30, 2026, highlighting a lean operating structure relative to its planned Phase 2 and Phase 1b development activities.
- $500M financing capacity available
- Forte filed a shelf registration statement for up to $500.0 million of securities in June 2026, preserving access to additional financing if needed.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger completion remains uncertain
- The proposed argenx transaction is expected to close in Q3 2026 but remains subject to conditions including tenders representing at least one share more than 50% of outstanding shares, regulatory clearances and other approvals. If terminated under specified circumstances, Forte may owe argenx a $65 million termination fee.
- Continued losses require future funding
- Forte states that it will require additional capital to complete FB102 clinical development despite having approximately $198.5 million of cash, cash equivalents and short-term investments as of June 30, 2026. The company reported a $45.5 million net loss for the six months ended June 30, 2026.
- Single-asset clinical concentration
- Forte’s long-term prospects depend on a single product candidate, FB102, which has no approved products behind it. FB102 remains in a Phase 2 celiac study and a Phase 1b alopecia areata study, so positive Phase 1b data from celiac disease in June 2025 and vitiligo in July 2026 may not predict later-stage outcomes.
- Transaction disruption and retention risk
- The pending transaction may restrict business activity and divert management attention; Forte has 23 full-time employees as of June 30, 2026, increasing potential execution and retention sensitivity during the transaction period.
- Deal-break risk to equity value
- Forte’s common stock closed at $76.79 per share on August 7, 2026, while the proposed transaction is exposed to a significant decline if the Offer or Merger is not completed during the expected Q3 2026 timeframe.
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects the argenx Offer and Merger to close during Q3 2026, and expects topline readouts from the FB102 Phase 1b alopecia areata trial and Phase 2 celiac study in the second half of 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Forte Biosciences reported a challenging quarter, with a substantial loss of $22.1 million despite maintaining $58.2 million in cash. Their lead candidate, FB102, continues in clinical trials with no revenue generated,…
- 10-K · March 31, 2026
- Forte Biosciences (FBRX) is a clinical-stage biopharmaceutical company focused on FB102, an anti-CD122 monoclonal antibody. The 10-K highlights positive Phase 1b celiac data (VCIEL p=0.0099) and progression to a Phase 2…
- 10-Q · August 14, 2025
- Forte (FBRX) reported no product revenue and posted a Q2 net loss of $11,249 (three months) or $(0.96) per share, an improvement versus the prior-year quarter net loss of $12,511 and EPS $(6.78). Cash increased…
- 10-K · March 28, 2025
- Forte is a clinical-stage biotech focused on FB102, an anti-CD122 monoclonal antibody that completed Phase 1 healthy volunteer cohorts with no dose-limiting toxicities and demonstrated pharmacodynamic signals (NK…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FBRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever